We may already have our partnership for LymPro in
Post# of 30028
Posted On: 09/08/2014 12:11:55 AM
We may already have our partnership for LymPro in the works. Even without the big upfront money now, that can come a short distance down the road. Here is an excerpt from JN's Zack's report from September 3rd.
Agreement with ICON Gets CLIA Ball Rolling
On September 2, 2014, Amarantus announced it had entered into a Master Service Agreement with ICON Central
Laboratories, a division of ICON PLC (NASDAQ: ICLR) to initiate CLIA development work on LymPro. Amarantus
has submitted an initial work order to ICON for delivery of the Fit for Purpose Flow Cytometry Assay Validation of
LymPro at ICON's CLIA-certified Central Laboratory facility in Farmingdale, NY. ICON offers central laboratory
testing and biomarker services to the biopharmaceutical industry and has central laboratories and support staff in
the United States, Ireland, Singapore, China and India. The Master Services Agreement covers all of ICON's
laboratory sites worldwide.
The Fit for Purpose Flow Cytometry Assay Validation is the Analytical Performance Package (APP) that
management has been alluding to as the critical set of experiments required to demonstrate that LymPro is a
commercial-grade test with required reproducibility. Amarantus believes this initial work at ICON will cost less than
$150,000 and data should be returned to the company in 6 to 8 weeks. We note that Amarantus is maintaining all
intellectual property rights to LymPro at the current time. The agreement with ICON is simply a services agreement
that gets the ball rolling on the CLIA process. This services agreement extends over four years and covers
LymPro s central laboratory requirements under CLIA. We note that under CLIA, only one laboratory facility can run
a Laboratory Developed Test, so if once LymPro is cleared under CLIA ICON has meaningful upside as the
contracted lab to run the test for Amarantus.
We believe this could turn into a full commercialization partnership for Amarantus in time . With this agreement,
Amarantus also gain access to a global distribution network for LymPro, including central laboratories in Europe,
Singapore, India and China that will allow LymPro to enter these new markets seamlessly through an already
established distribution framework. In addition, ICON is also providing to Amarantus consulting support for
eltoprazine and MANF .
The full report is here:
http://scr.zacks.com/files/September-3-2014_A...r089j6.pdf
Agreement with ICON Gets CLIA Ball Rolling
On September 2, 2014, Amarantus announced it had entered into a Master Service Agreement with ICON Central
Laboratories, a division of ICON PLC (NASDAQ: ICLR) to initiate CLIA development work on LymPro. Amarantus
has submitted an initial work order to ICON for delivery of the Fit for Purpose Flow Cytometry Assay Validation of
LymPro at ICON's CLIA-certified Central Laboratory facility in Farmingdale, NY. ICON offers central laboratory
testing and biomarker services to the biopharmaceutical industry and has central laboratories and support staff in
the United States, Ireland, Singapore, China and India. The Master Services Agreement covers all of ICON's
laboratory sites worldwide.
The Fit for Purpose Flow Cytometry Assay Validation is the Analytical Performance Package (APP) that
management has been alluding to as the critical set of experiments required to demonstrate that LymPro is a
commercial-grade test with required reproducibility. Amarantus believes this initial work at ICON will cost less than
$150,000 and data should be returned to the company in 6 to 8 weeks. We note that Amarantus is maintaining all
intellectual property rights to LymPro at the current time. The agreement with ICON is simply a services agreement
that gets the ball rolling on the CLIA process. This services agreement extends over four years and covers
LymPro s central laboratory requirements under CLIA. We note that under CLIA, only one laboratory facility can run
a Laboratory Developed Test, so if once LymPro is cleared under CLIA ICON has meaningful upside as the
contracted lab to run the test for Amarantus.
We believe this could turn into a full commercialization partnership for Amarantus in time . With this agreement,
Amarantus also gain access to a global distribution network for LymPro, including central laboratories in Europe,
Singapore, India and China that will allow LymPro to enter these new markets seamlessly through an already
established distribution framework. In addition, ICON is also providing to Amarantus consulting support for
eltoprazine and MANF .
The full report is here:
http://scr.zacks.com/files/September-3-2014_A...r089j6.pdf
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼